In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
SILO Pharma's net current asset value per share for the quarter that ended in Mar. 2025 was $0.83.
The historical rank and industry rank for SILO Pharma's Net Current Asset Value or its related term are showing as below:
SILO'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.66 Med: 6.61 Max: 1000
Current: 0.71
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of SILO Pharma was 1000.00. The lowest was 0.66. And the median was 6.61.
SILO's Price-to-Net-Current-Asset-Value is ranked better than 91.07% of 985
companies
in the Biotechnology industry
Industry Median: 3.86
vs SILO: 0.71
SILO Pharma Net Current Asset Value Historical Data
The historical data trend for SILO Pharma's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of SILO Pharma's Net Current Asset Value
For the Biotechnology subindustry, SILO Pharma's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SILO Pharma's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SILO Pharma's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where SILO Pharma's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SILO Pharma (NAS:SILO) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
SILO Pharma Net Current Asset Value Related Terms
Thank you for viewing the detailed overview of SILO Pharma's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SILO has been successfully added to your 